GoAI
Get started
Kalaris Therapeutics Inc logo

Kalaris Therapeutics Inc

KLRS

NASDAQHealthcareBiotechnology

Open in GoAI

Latest quote

$4.15

+$0.03 · +0.73%

Aug 21, 3:55 PM ET

KLRS company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

54

Fair Value

Momentum

22

Weakening

Sentiment

65

Bullish

Risk resilience

34

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), as well as for the treatment of other exudative and neovascular retinal diseases.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Andrew Oxtoby
Listed since
Jul 30, 2020
Employees
20

Market position

Volume
81.24K
0.39× average
Average volume
209.6K
Average daily volume
Market cap
90.58M USD
Beta
0.19
Market reference 1

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
32.25M USD
P/E (TTM)
-2.05×
P/B (TTM)
1.71×
P/S (TTM)
0×
EV / EBITDA
-0.77×
Earnings yield
-33.71%
Free cash flow yield
-33.51%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
0.00%
Operating margin
0.00%
Net margin
0.00%
Return on equity
-55.11%
Return on assets
-35.68%
Return on invested capital
-41.08%

Financial health

Debt / equity
0.02×
Current ratio
12.23×
Altman Z-score
-1.71
Piotroski F-score
0 of 9

Financial statements

Income trends

Operating income

−46.15M USD+16.48%

Net income

−43.44M USD+26.09%
Income trends across reported periods2.39M USD−61.01M USD−124.41M USD−187.81M USDOperating income, FY2021: −169.82M USDOperating income, FY2022: −14.01M USDOperating income, FY2023: −13.46M USDOperating income, FY2024: −55.26M USDOperating income, FY2025: −46.15M USDNet income, FY2021: −171.96M USDNet income, FY2022: −15.49M USDNet income, FY2023: −14.7M USDNet income, FY2024: −58.77M USDNet income, FY2025: −43.44M USDFY2021FY2022FY2023FY2024FY2025
Operating income FY2021 −169.82M USD. Operating income FY2022 −14.01M USD. Operating income FY2023 −13.46M USD. Operating income FY2024 −55.26M USD. Operating income FY2025 −46.15M USD. Net income FY2021 −171.96M USD. Net income FY2022 −15.49M USD. Net income FY2023 −14.7M USD. Net income FY2024 −58.77M USD. Net income FY2025 −43.44M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Cost of goods sold13K USD———1.12M USD
Gross profit−13K USD———−1.12M USD
Research and development30.75M USD12.34M USD11.71M USD11.76M USD119.62M USD
Selling, general, and administrative15.39M USD42.92M USD1.76M USD2.24M USD49.08M USD
Operating expenses46.14M USD55.26M USD13.46M USD14.01M USD168.7M USD
Interest income—5.49M USD——1.32M USD
Interest expense1.44M USD—687K USD235K USD—
Depreciation and amortization13K USD———1.12M USD
Operating income−46.15M USD−55.26M USD−13.46M USD−14.01M USD−169.82M USD
Net income−43.44M USD−58.77M USD−14.7M USD−15.49M USD−171.96M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
64%
7 beats, 4 misses, 0 met estimates
Average EPS surprise
-7.67%
11 comparable reports
Latest EPS result
-0.48
Estimate -0.5 · Beat by 3.03%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.37-1.55-2.72-3.89Q1 '25MissQ2 '25MissQ3 '25MissQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 7, 2025: actual -3.64, estimate -2.76, surprise -31.84%, Miss. Q2 2025, reported May 14, 2025: actual -2.52, estimate -0.78, surprise -223.08%, Miss. Q3 2025, reported Aug 13, 2025: actual -0.61, estimate -0.51, surprise -19.61%, Miss. Q4 2025, reported Nov 12, 2025: actual -0.64, estimate -0.66, surprise +3.03%, Beat. Q1 2026, reported Mar 17, 2026: actual -0.44, estimate -0.56, surprise +21.43%, Beat. Q2 2026, reported May 12, 2026: actual -0.46, estimate -0.52, surprise +11.54%, Beat. Q3 2026, reported Aug 11, 2026: actual -0.48, estimate -0.495, surprise +3.03%, Beat. Q4 2026, reported Nov 11, 2026: actual —, estimate -0.52, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$18.00

333.73% upside
Past 12 months12-month forecastHigh $23.00Average $18.00Low $14.00

KLRS peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding KLRS

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
896.23K
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
482.18K
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Micro-Cap ETF logoiShares Micro-Cap ETFIWC
Market value
108.22K
Weight
0.01%
AUM
1.53B USD
Expense ratio
0.60%
Price / 1D
$198.39+1.10%
Dimensional - US Core Equity 1 ETF logoDimensional - US Core Equity 1 ETFDCOR
Market value
13.68K
Weight
0.00%
AUM
3.51B USD
Expense ratio
0.14%
Price / 1D
$84.54+0.42%
Dimensional - US Core Equity 2 ETF logoDimensional - US Core Equity 2 ETFDFAC
Market value
10.85K
Weight
0.00%
AUM
49.31B USD
Expense ratio
0.17%
Price / 1D
$45.61+0.46%

Continue in GoAI

Research KLRS

research.disclaimer